Kripa N. Nand

Kripa N. Nand

Auto-generated profile, based on publicly available information

Kripa N. Nand

Department of Biological Sciences, Rensselaer Polytechnic Institute, Troy, NY 12180, USA

Research Focus & Metrics

Academic Career Length

4Years (2023-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
18 February 2023 in Vaccines
Verified
Journal Article
Open access
PDF file
VSVartika Srivastava
Vartika Srivastava
KNKripa N. Nand
Kripa N. Nand
AAAijaz Ahmad
Aijaz Ahmad
FNU RAVINDER KUMARFNU RAVINDER KUMAR
FNU RAVINDER KUMAR
Virus-like particles (VLPs) are empty, nanoscale structures morphologically resembling viruses. Internal cavity, noninfectious, and particulate nature with a high density of repeating epitopes, make them an ideal platform for vaccine development and drug delivery. Commercial use of Gardasil-9 and Cervarix showed the usefulness of VLPs in vaccine formulation. Further, chimeric VLPs allow the raising of an immune response against different immunogens and thereby can help reduce the generation of medical or clinical waste. The economically viable production of VLPs significantly impacts their usage, application, and availability. To this end, several hosts have been used and tested. The present review will discuss VLPs produced using different yeasts as fermentation hosts. We also compile a list of studies highlighting the expression and purification of VLPs using a yeast-based platform. We also discuss the advantages of using yeast to generate VLPs over other available systems. Further, the issues or limitations of yeasts for producing VLPs are also summarized. The review also compiles a list of yeast-derived VLP-based vaccines that are presently in public use or in different phases of clinical trials.